Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects

British Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2004, Pages 181-187

  Kyrklund, Carl ^a   Backman, Janne T ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Interaction; Pravastatin; Rifampicin

Indexed keywords

PLACEBO; PRAVASTATIN; RIFAMPICIN; RIFARM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METHODOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLASMA; PRAVASTATIN; RIFAMPIN;

EID: 1242284362     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01972.x     Document Type: Article

References (32)

1. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
2. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-8.
3. Combalbert J, Fabre I, Fabre G et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
4. Greiner B, Eichelbaum M, Fritz P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53.
5. Fromm MF, Kauffmann HM, Fritz P et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-80.
6. Kliewer SA, Moore JT, Wade L et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73-82.
7. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
8. Tirona RC, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304: 223-8.
9. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592-7.
10. Jacobsen W, Kirchner G, Hallensleben K et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999; 291: 131-9.
11. Jacobsen W, Kirchner G, Hallensleben K et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27: 173-9.
12. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991; 19: 740-8.
13. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 1997; 25: 1123-9.
14. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-8.
15. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002; 54: 1343-52.
16. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41.
17. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers. ACTG Study A5047 AIDS 2002; 16: 569-77.
18. Mulvana D, Jemal M, Pulver SC. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal 2000; 23: 851-66.
19. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183-92.
20. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988; 33: 454-62.
21. Ecker G, Chiba P. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein - an overview. Wien Klin Wochenschr 1995; 107: 681-6.
22. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002; 41: 65-74.
23. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-72.
24. Doostdar H, Grant MH, Melvin WT, Wolf CR, Burke MD. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol 1993; 46: 629-35.
25. Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981; 12: 149-53.
26. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly. effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67: 512-20.
27. Sugimoto K, Ohmori M, Tsuruoka S et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-24.
28. Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-16.
29. Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol 1994; 73: 18D-24D.
30. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampicin markedly decreases the concentrations of atorvastatin and its metabolites [abstract]. 18th European workshop on drug metabolism Abstract book, 2002: 83.
31. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61.
32. Vickers S, Duncan CA, Vyas KP et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990; 18: 476-83.